ESMO 2020 | CHRYSALIS trial update in NSCLC

Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea, discusses the Phase I CHRYSALIS study (NCT02609776), investigating the use of amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, in combination with lazertinib, a third-generation tyrosine kinase inhibitor (TKI), in advanced EGFR non-small-cell lung cancer (NSCLC). The study showed encouraging preliminary activity in patients with osimertinib-relapsed disease. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).